Strategically Located for Cross-Regional and Multinational Success
With its founding partners headquartered in Berlin, Germany, and Cairo, Egypt, MiGenTra is uniquely positioned to reap the benefits of a solid foothold in the MEA region and a significant European customer base.
Specialised in the Development and Manufacturing of Complex Therapeutic Proteins
Specialized in the development and manufacturing of complex therapeutic proteins, ProBioGen is a Contract Development and Manufacturing Organization (CDMO), a technology provider located in Berlin, Germany, and a subsidiary of Minapharm Pharmaceuticals in Egypt. With over 25 years of experience, ProBioGen is a sought-after partner along the entire drug development value chain up to clinical phase III.
The company’s over 220 employees include internationally acclaimed scientists specialized in biopharmaceutical cell development and technology, protein chemistry, and molecular biology. ProBioGen also has extensive knowledge and expertise in the development of viral vector platforms and gene-based therapies. ProBioGen also provides process development services and manufacturing technologies for viral vaccines.
With its intelligent technologies and state-of-the-art platforms, ProBioGen generates biologics with optimized properties. With a comprehensive quality management system, the company ensures compliance with international ISO and GMP standards (EMA/FDA). In order to meet high customer demand, the company is expanding its current headquarters to increase production capacity by adding an additional 1000 L single-use bioreactor soon.
- 2 locations in Berlin, Germany
- Subsidiary of Minapharm Pharmaceuticals SE
- More than 220 employees
- Renowned CDMO and technology provider with extensive expertise in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals
- 2000 L bioreactor capacity
- Headquartered in Cairo
- Over 1400 employees
- Most advanced biological drug developer and manufacturer in Egypt for the MENA region
- Commercialization of over 100 products from small molecules to complex genetically engineered proteins
State-of-the-Art Pharmaceutical and Biopharmaceutical Research Technologies Made Affordable
Minapharm has dedicated 50 years to ensuring patients in developing countries also benefit from state-of-the-art pharmaceutical and biopharmaceutical research technologies. As the sole gene-to-market biopharmaceutical company in the MEA region, Minapharm is positioned to play a vital role in the development and manufacture of Biosimilars, Cell and Gene Therapies (CGT), and vaccines for the MEA region.
With over 1400 employees, the company maintains a diverse product portfolio that covers an extensive range of medical products, from small molecules to complex bioengineering proteins. In its effort to direct the region’s focus towards biologicals, the company has already set up a second manufacturing facility to help meet its short and medium-term biotechnology and gene therapy business goals.
Together with its wholly owned Berlin-based subsidiary, ProBioGen AG, Minapharm has established an integrated business model making it the only gene-to-market biopharmaceutical company in the region to date.